Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think [Seeking Alpha]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Seeking Alpha
Competition in IgAN from larger players like Novartis and Vertex is intensifying, making FILSPARI's FSGS approval pivotal for the company's future growth. FILSPARI's FSGS indication represents a $2 billion U.S. peak sales opportunity, with no current FDA-approved therapies for this disease. Phase 2 and 3 trials showed statistically significant proteinuria reduction for FILSPARI in FSGS, supporting strong approval prospects if this endpoint is accepted. slobo/iStock via Getty Images Introduction Travere Therapeutics ( TVTX ) is a San Diego-based biopharmaceutical company specialized in rare kidney and metabolic diseases, with the key product FILSPARI (sparsentan) that is fully approved for IgA Nephropathy (IgAN). It was slated for a PDUFA decision on Jan 13, 2026, for focal segmental glomerulosclerosis (FSGS), but This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of TVTX either through stock ownership, options, or other
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) had its "neutral" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech SummitBusiness Wire
- Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative? [Yahoo! Finance]Yahoo! Finance
- TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law FirmGlobeNewswire
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 2/9/26 - Form SCHEDULE
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- TVTX's page on the SEC website